Supraflex Cruz's safety and effectiveness proven in elderly heart attack patients over a 3-year period, as per findings from the FIRE Trial.
Sahajanand Medical Technologies (SMT), a global medical devices company, has made a significant breakthrough in the field of cardiology with the results of the FIRE Trial. The study, which evaluates revascularization strategies in elderly MI patients with multivessel disease, has shown promising results.
The trial, led by Professor Gianluca Campo, demonstrated that physiology-guided complete revascularization using SMT's Supraflex Cruz drug-eluting stent (DES) lowered the risk of a composite endpoint of death, MI, stroke, or ischemia-driven revascularization compared to a culprit-only approach.
The primary endpoint of the FIRE Trial was the patient-oriented composite of all-cause death, MI, stroke, and revascularization, assessed over three years. At a 3-year follow-up, physiology-guided complete revascularization, as compared to a culprit-only revascularization strategy, reduced the risk of primary and key secondary endpoints.
The Supraflex Cruz DES is part of the Supraflex family of stents, which have been proven to be clinically safe and effective in comparison to other DES in clinical practice. This assertion is backed by a series of clinical trials, including the TALENT trial.
Professor Campo, the Study Chair, stated, "The FIRE Trial demonstrates that physiology-guided complete revascularization using Supraflex Cruz lowered the risk of a composite endpoint of death, MI, stroke, or ischemia-driven revascularization compared to a culprit-only approach." Dr. Simone Biscaglia, Principal Investigator, added, "The FIRE Trial shows that physiology-guided complete revascularization with Supraflex Cruz offers benefits in elderly MI patients with multivessel disease."
Dr. Krishna Sudhir, Chief Medical Officer of SMT, commented, "The FIRE Trial reinforces evidence from other studies showing Supraflex Cruz consistently delivers positive outcomes in high-risk patients."
SMT, which was the first company in the world to receive CE certification for a DES with a biodegradable polymer, has a global presence with operations in more than 75 countries as of March 31, 2025. The details of the initial public offer can be found on SMT's website and the websites of SEBI, Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited, Nuvama Wealth Management Limited, and the stock exchanges.
However, it is important to note that investment in equity shares involves a high degree of risk, and potential investors should refer to the Red Herring Prospectus for details, including the section titled 'Risk Factors'. Potential investors should not rely on the draft red herring prospectus for any investment decision.
The Supraflex Cruz DES is a medical device used in vascular and structural heart intervention. SMT's portfolio includes technologically advanced medical devices for vascular and structural heart intervention.
In conclusion, the results of the FIRE Trial show consistently low stent thrombosis rates (1.03% at 1 year; 1.17% at 3 years) and a lowered risk of adverse cardiovascular events, making Supraflex Cruz a significant advancement in cardiology.
Read also:
- Top-Notch Home and Expert Age Spot Remedies
- 'Starting today, registration for the Ayushman Bharat Scheme is available'; announced Delhi's Health Minister, Pankaj Kumar Singh
- Apparition's Significance and its Delivered Messages - as discussed by Sensenmann
- Explored the Popular Health Assessment with a Queue of 100,000 Aspiring Participants - Here's My Unadulterated Opinion
